Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
overt hepatic encephalopathy epidemiology forecast insight

SALE

Overt Hepatic Encephalopathy - Epidemiology Forecast - 2034

Published Date : 2025

Pages : 100

Region : United States, Japan, 7MM, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
- Sample Request

overt hepatic encephalopathy epidemiology forecast insight

DelveInsight’s 'Overt Hepatic Encephalopathy (OHE) - Epidemiology Forecast–2034’ report delivers an in-depth understanding of the Overt Hepatic Encephalopathy (OHE), historical and forecasted epidemiology as well as the Overt Hepatic Encephalopathy (OHE) epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geographies Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2021-2034

Overt Hepatic Encephalopathy (OHE) Disease Understanding

Hepatic encephalopathy (HE) is a brain disorder that develops in some individuals with liver disease. HE presents as a spectrum of neuropsychiatric symptoms ranging from subtle fluctuating cognitive impairment to coma and is a significant contributor to morbidity in patients with liver disease. It is observed in acute liver failure, liver bypass procedures – for example, shunt surgery and trans-jugular intrahepatic portosystemic shunt – and cirrhosis, classified as Type A, B, and C HE, respectively. Pathogenesis is linked with ammonia and glutamine production.

Moreover, HE can be associated with more severe symptoms, including reduced alertness, shortened attention span, disruptions in sleep patterns, mild confusion, slowing ability to perform mental tasks, and mood or personality changes. More noticeable changes in memory, concentration, or intellectual function than in minimal hepatic encephalopathy (MHE) may also be observed. HE can also be classified according to whether its presence is overt or covert. When affected individuals have obvious, outward signs and symptoms, the disorder may be referred to as overt hepatic encephalopathy (OHE).

Overt Hepatic Encephalopathy (OHE) Diagnosis

The HE diagnosis is based on the presence of a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction after excluding unrelated neurologic and/or metabolic causes of encephalopathy. The diagnosis of OHE is made after excluding other causes of encephalopathy and mental status changes. In addition to making the diagnosis of OHE, it is imperative to identify and address precipitating factors of OHE, such as infection, upper gastrointestinal bleeding, medications, or electrolyte/volume disturbances.

Overt Hepatic Encephalopathy (OHE) Epidemiology Perspective by DelveInsight’s

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Hepatic Encephalopathy, Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy, Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy, and Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

Overt Hepatic Encephalopathy (OHE) Detailed Epidemiology Segmentation

Total diagnosed prevalent cases of Hepatic Encephalopathy (HE) in the 7MM were found to be 337,013 in 2020.
The epidemiology model of OHE is based on the various published literature related to cirrhosis and its hospitalization. We also conducted interviews with the key opinion leaders (KOLs) to fill the gaps and confirm the findings of the secondary search.
Assessments as per DelveInsight analysis, the US accounted for the majority of Hepatic Encephalopathy cases in the 7MM with 205,018 diagnosed prevalent cases in 2020.
The age‐specific data revealed that the highest number of Hepatic Encephalopathy people affected with was found in the age group of 45–54 years, while people <25 years are the least affected.
Assessments as per DelveInsight’s analysts show that the majority of cases of Hepatic Encephalopathy are males. There was a total of 149,048 male and 55,970 female cases of Hepatic Encephalopathy in 2020 in the United States.
HE is divided into two broad categories based on severity, Covert Hepatic Encephalopathy (CHE) and Overt Hepatic Encephalopathy (OHE). There was a total of 82,007 OHE cases in 2020 in the United States which is expected to increase at a CAGR of 0.79% for the study period 2021-2034.
In EU-5, the United Kingdom has the highest number of cases of OHE with 10,971 cases in 2020, followed by Germany with 10,669 cases and France with 8,910 cases. While Spain reported the least number of cases i.e. 3,923 in 2020.
In 2020, Japan had 11,829 diagnosed prevalent cases of OHE. These cases are expected to increase by 2034 at a CAGR of 0.20%.

Scope of the Report

The report covers the descriptive overview of OHE, explaining its signs and symptoms, causes, and diagnosis.
The report provides insight into the 7MM historical and forecasted patient population covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The report assesses the disease risk and burden of Overt Hepatic Encephalopathy (OHE).
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

Report Highlights

10-Year Forecast of Overt Hepatic Encephalopathy (OHE)
7MM Coverage
Total Diagnosed Prevalent Cases of Hepatic Encephalopathy
Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy
Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy
Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy

Key Questions Answered

What are the disease risk and burdens of Overt Hepatic Encephalopathy (OHE)?
What is the historical Overt Hepatic Encephalopathy (OHE) patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
What would be the forecasted patient population of Overt Hepatic Encephalopathy (OHE) at the 7MM level?
What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Overt Hepatic Encephalopathy (OHE)?
Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of Overt Hepatic Encephalopathy (OHE) during the forecast period (2025-2034)?
At what CAGR the population is expected to grow across the 7MM during the forecast period (2025-2034)?

Reasons to buy

The Overt Hepatic Encephalopathy (OHE) report will allow the user to -

Develop business strategies by understanding the trends shaping and driving the 7MM Overt Hepatic Encephalopathy (OHE) epidemiology forecast.
The Overt Hepatic Encephalopathy (OHE) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
The Overt Hepatic Encephalopathy (OHE) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Overt Hepatic Encephalopathy (OHE) Epidemiology Overview at a Glance

3.1. Patient Share (%) Distribution of OHE in 2018

3.2. Patient Share (%) Distribution of OHE in 2030

4. Executive Summary of Overt Hepatic Encephalopathy (OHE)

5. Disease Background and Overview

5.1. Introduction

5.2. Classification of Hepatic Encephalopathy (HE)

5.3. Symptoms

5.4. Cause and Risk Factors

5.5. Pathophysiology

5.6. Pathogenesis

5.7. Diagnosis

5.7.1. Differential Diagnosis for HE

5.7.2. Diagnostic Algorithm

5.7.3. Diagnostic Guidelines

5.7.3.1. Hepatic Encephalopathy in Chronic Liver Disease 2014 Practice Guideline by AASLD and EASL

5.7.3.2. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF)

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Methodology of Epidemiology

6.3. Assumptions and Rationale: 7MM

6.4. Total Diagnosed Prevalent Cases of Cirrhosis (Hospitalization Cases of Cirrhosis) in the 7MM

6.5. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy (HE) in the 7MM

6.6. Total Diagnosed Prevalent Cases of Overt Hepatic Encephalopathy (OHE) in the 7MM

6.7. The United States

6.7.1. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United States

6.7.2. Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United States

6.7.3. Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United States

6.7.4. Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United States

6.8. EU-5

6.8.1. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU-5

6.8.2. Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU-5

6.8.3. Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU-5

6.8.4. Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU-5

6.9. Japan

6.9.1. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy Cases in Japan

6.9.2. Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan

6.9.3. Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan

6.9.4. Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan

7. Patient Journey

8. KOL Views

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Tables:

List of Tables

Table 1: Summary of OHE Epidemiology (2021-2034)

Table 2: Clinical Description of Hepatic Encephalopathy (Adapted from AASLD-EASL Guideline, 2014)

Table 3: West Haven Criteria for HE and symptoms

Table 4: The Five Clinical Patterns of HE Presentation

Table 5: Stages of HE

Table 6: Differential Diagnosis: Alternative Causes of Encephalopathy Depending on Clinical Patterns

Table 7: Total Diagnosed Prevalent Cases of Cirrhosis (Hospitalization Cases of Cirrhosis) in the 7MM (2021-2034)

Table 8: Total Diagnosed Prevalent Cases of Hepatic Encephalopathy (HE) in the 7MM (2021-2034)

Table 9: Total Diagnosed Prevalent Cases of Overt Hepatic Encephalopathy (OHE) in the 7MM (2021-2034)

Table 10: Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the US (2021-2034)

Table 11: Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the US (2021-2034)

Table 12: Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United States (2021-2034)

Table 13: Type-Specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the US (2021-2034)

Table 14: Total Diagnosed Prevalent Cases of Hepatic Encephalopathy Cases in EU-5 (2021-2034)

Table 15: Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU-5 (2021-2034)

Table 16: Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU5 (2021-2034)

Table 17: Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU5 (2021-2034)

Table 18: Total Diagnosed Prevalent Cases of Hepatic Encephalopathy Cases in Japan (2021-2034)

Table 19: Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan (2021-2034)

Table 20: Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan (2021-2034)

Table 21: Type-Specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan (2021-2034)

List of Figures:

List of Figures

Figure 1: Symptoms of HE

Figure 2: Grading of the symptoms of HE

Figure 3: Risk Factors of HE

Figure 4: Pathophysiology of HE

Figure 5: Ammonia Trafficking in HE from an Organism (left panel) and an Organ (right panel) Perspective

Figure 6: Diagnostic tree for HE, ammonia reducing treatments

Figure 7: The Classification of HE

Figure 8: Total Diagnosed Prevalent Cases of Cirrhosis (Hospitalization Cases of Cirrhosis) in the 7MM (2021-2034)

Figure 9: Total Diagnosed Prevalent Cases of Hepatic Encephalopathy (HE) in the 7MM (2021-2034)

Figure 10: Total Diagnosed Prevalent Cases of Overt Hepatic Encephalopathy (OHE) in the 7MM (2021-2034)

Figure 11: Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the US (2021-2034)

Figure 12: Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the US (2021-2034)

Figure 13: Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the US (2021-2034)

Figure 14: Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in the US (2021-2034)

Figure 15: Total Diagnosed Prevalent Cases of Hepatic Encephalopathy Cases in EU-5 (2021-2034)

Figure 16: Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU-5 (2021-2034)

Figure 17: Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU-5 (2021-2034)

Figure 18: Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in EU-5 (2021-2034)

Figure 19: Total Diagnosed Prevalent Cases of Hepatic Encephalopathy Cases in Japan (2021-2034)

Figure 20: Gender-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan (2021-2034)

Figure 21: Age-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan (2021-2034)

Figure 22: Type-specific Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan (2021-2034)

Figure 23: Patient Journey

Tags:

License Type

Offer